180 related articles for article (PubMed ID: 23651947)
1. VPAC1 receptors for imaging breast cancer: a feasibility study.
Thakur ML; Zhang K; Berger A; Cavanaugh B; Kim S; Channappa C; Frangos AJ; Wickstrom E; Intenzo CM
J Nucl Med; 2013 Jul; 54(7):1019-25. PubMed ID: 23651947
[TBL] [Abstract][Full Text] [Related]
2. Imaging spontaneous MMTVneu transgenic murine mammary tumors: targeting metabolic activity versus genetic products.
Thakur ML; Devadhas D; Zhang K; Pestell RG; Wang C; McCue P; Wickstrom E
J Nucl Med; 2010 Jan; 51(1):106-11. PubMed ID: 20008985
[TBL] [Abstract][Full Text] [Related]
3. Targeting VPAC1 Receptors for Imaging Glioblastoma.
Tripathi SK; Kean R; Bongiorno E; Hooper DC; Jin YY; Wickstrom E; McCue PA; Thakur ML
Mol Imaging Biol; 2020 Apr; 22(2):293-302. PubMed ID: 31292914
[TBL] [Abstract][Full Text] [Related]
4. VPAC1 Targeted (64)Cu-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man.
Tripathi S; Trabulsi EJ; Gomella L; Kim S; McCue P; Intenzo C; Birbe R; Gandhe A; Kumar P; Thakur M
Urology; 2016 Feb; 88():111-8. PubMed ID: 26519886
[TBL] [Abstract][Full Text] [Related]
5. VPAC1 Targeted
Tripathi SK; Kumar P; Trabulsi EJ; Kim S; McCue PA; Intenzo C; Berger A; Gomella L; Thakur ML
Nucl Med Biol; 2017 Aug; 51():55-61. PubMed ID: 28577428
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation.
Zhang K; Aruva MR; Shanthly N; Cardi CA; Patel CA; Rattan S; Cesarone G; Wickstrom E; Thakur ML
Regul Pept; 2007 Dec; 144(1-3):91-100. PubMed ID: 17727979
[TBL] [Abstract][Full Text] [Related]
7. VPAC1-targeted PET/CT scan: improved molecular imaging for the diagnosis of prostate cancer using a novel cell surface antigen.
Truong H; Gomella LG; Thakur ML; Trabulsi EJ
World J Urol; 2018 May; 36(5):719-726. PubMed ID: 29541892
[TBL] [Abstract][Full Text] [Related]
8. PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog.
Thakur ML; Aruva MR; Gariepy J; Acton P; Rattan S; Prasad S; Wickstrom E; Alavi A
J Nucl Med; 2004 Aug; 45(8):1381-9. PubMed ID: 15299065
[TBL] [Abstract][Full Text] [Related]
9. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.
Mortimer JE; Bading JR; Colcher DM; Conti PS; Frankel PH; Carroll MI; Tong S; Poku E; Miles JK; Shively JE; Raubitschek AA
J Nucl Med; 2014 Jan; 55(1):23-9. PubMed ID: 24337604
[TBL] [Abstract][Full Text] [Related]
10. PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer.
Zhang K; Aruva MR; Shanthly N; Cardi CA; Rattan S; Patel C; Kim C; McCue PA; Wickstrom E; Thakur ML
J Nucl Med; 2008 Jan; 49(1):112-21. PubMed ID: 18077536
[TBL] [Abstract][Full Text] [Related]
11. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.
Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C
J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766
[TBL] [Abstract][Full Text] [Related]
12. Imaging urothelial bladder cancer: A VPAC PET targeted approach.
Thakur ML; Tripathi SK; Gomella LG; Salmanoglu E; Kim S; Kelly WK; Keith SW; Intenzo C; McCue P; Hoffman-Censits J; Trabulsi EJ
Can J Urol; 2021 Apr; 28(2):10596-10602. PubMed ID: 33872557
[TBL] [Abstract][Full Text] [Related]
13. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
[TBL] [Abstract][Full Text] [Related]
14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
15. Newly-Developed Positron Emission Mammography (PEM) Device for the Detection of Small Breast Cancer.
Yanai A; Itoh M; Hirakawa H; Yanai K; Tashiro M; Harada R; Yoshikawa A; Yamamoto S; Ohuchi N; Ishida T
Tohoku J Exp Med; 2018 May; 245(1):13-19. PubMed ID: 29731479
[TBL] [Abstract][Full Text] [Related]
16. Background ¹⁸F-FDG uptake in positron emission mammography (PEM): correlation with mammographic density and background parenchymal enhancement in breast MRI.
Koo HR; Moon WK; Chun IK; Eo JS; Jeyanth JX; Chang JM; Cho N; Kang KW
Eur J Radiol; 2013 Oct; 82(10):1738-42. PubMed ID: 23806533
[TBL] [Abstract][Full Text] [Related]
17. Analysis of incidental focal hypermetabolic uptake in the breast as detected by 18F-FDG PET/CT: clinical significance and differential diagnosis.
Chae EY; Cha JH; Kim HH; Shin HJ; Kim HJ; Oh HY; Koh YH; Moon DH
Acta Radiol; 2012 Jun; 53(5):530-5. PubMed ID: 22593124
[TBL] [Abstract][Full Text] [Related]
18. 89Zr-bevacizumab PET imaging in primary breast cancer.
Gaykema SB; Brouwers AH; Lub-de Hooge MN; Pleijhuis RG; Timmer-Bosscha H; Pot L; van Dam GM; van der Meulen SB; de Jong JR; Bart J; de Vries J; Jansen L; de Vries EG; Schröder CP
J Nucl Med; 2013 Jul; 54(7):1014-8. PubMed ID: 23651946
[TBL] [Abstract][Full Text] [Related]
19. Positron emission mammography: correlation of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status and 18F-FDG.
Wang CL; MacDonald LR; Rogers JV; Aravkin A; Haseley DR; Beatty JD
AJR Am J Roentgenol; 2011 Aug; 197(2):W247-55. PubMed ID: 21785049
[TBL] [Abstract][Full Text] [Related]
20. Positron emission mammography in the diagnosis of breast cancer. Is maximum PEM uptake value a valuable threshold for malignant breast cancer detection?
Müller FH; Farahati J; Müller AG; Gillman E; Hentschel M
Nuklearmedizin; 2016; 55(1):15-20. PubMed ID: 26627876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
